

MINIREVIEW

Antibody Structure, Instability, and Formulation

WEI WANG, SATISH SINGH, DAVID L. ZENG, KEVIN KING, SANDEEP NEMA

Pfizer, Inc., Global Biologics, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017

Received 14 March 2006; revised 17 May 2006; accepted 4 June 2006

Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.20727

ABSTRACT: The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are in development. Although antibodies share certain structural similarities, development of commercially viable antibody pharmaceuticals has not been straightforward because of their unique and somewhat unpredictable solution behavior. This article reviews the structure and function of antibodies and the mechanisms of physical and chemical instabilities. Various aspects of formulation development have been examined to identify the critical attributes for the stabilization of antibodies. © 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96:1–26, 2007

Keywords: biotechnology; stabilization; protein formulation; protein aggregation; freeze drying/lyophilization

INTRODUCTION

Protein therapies are entering a new era with the influx of a significant number of antibody pharmaceuticals. Generally, protein drugs are effective at low concentrations with less side effects relative to small molecule drugs, even though, in rare cases, protein-induced antibody formation could be serious.¹ Therefore, this category of therapeutics is gaining tremendous momentum and widespread recognition both in small and large drug firms. Among protein drug therapies, antibodies play a major role in controlling many types of diseases such as cancer, infectious diseases, allergy, autoimmune diseases, and inflammation. Since the approval of the first monoclonal antibody (MAb) product -OKT-3 in 1986, more than 23 MAb drug products have entered the market (Tab. 1). The estimated number of antibodies and antibody derivatives constitute 20% of biopharmaceutical products

currently in development (about 200).² The global therapeutic antibody market was predicted to reach \$16.7 billion in 2008.³

There are several reasons for the increasing popularity of antibodies for commercial development. First, their action is specific, generally leading to fewer side effects. Second, antibodies may be conjugated to another therapeutic entity for efficient delivery of this entity to a target site, thus reducing potential side effects. For instance, Mylotarg is an approved chemotherapy agent composed of calicheamicin conjugated to humanized IgG4, which binds specifically to CD33 for the treatment of CD33-positive acute myeloid leukemia. Another example is the conjugation of immunotoxic barnase with the light chain of the anti-human ferritin monoclonal antibody F11 as potential targeting agents for cancer immunotherapy.⁴ Third, antibodies may be conjugated to radioisotopes for specific diagnostic purposes. Examples include CEA-Scan for detection of colorectal cancer and ProstaScint for detection of prostate cancer. Lastly, technology advancement has made complete human MAb available, which are less immunogenic.

Correspondence to: Wei Wang (Telephone: (636)-247-2111; Fax: (636)-247-5030; E-mail: wei.2.wang@pfizer.com)

Journal of Pharmaceutical Sciences, Vol. 96, 1–26 (2007)
© 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Table 1. Commercial Monoclonal Antibody Products

#	Brand name	Molecule	MAb	Year	Company	Route	Indication	MAb Conc	Buffer	Excipients	Surfactant	pH
1	Avastin	Bevacizumab	Humanized IgG1, 149 kDa	2004	Genetech and BioOncology	IV infusion	Metastatic carcinoma of colon or rectum, binds VEGF	100 mg and 400 mg/vial (25 mg/mL) solution	5.8 mg/mL monobasic NaPhos H_2O ; 1.2 mg/mL dibasic NaPhos anhydrous (4 mL, 16 mL fill in vial)	60 mg/mL α -Trehalose dihydrate (4 mL, 16 mL fill in vial)	0.4 mg/mL PS20 (4 mL, 16 mL fill in vial)	6.2
2	Bexxar	Tositumomab and I-131Tositumab	Murine IgG2a	2003	Corixa and GSK	IV Infusion	CD20 positive follicular nonHodgkins lymphoma	Kit: 14 mg/mL MAb solution in 35 mg and 225 mg vials; 1.1 mg/mL I131-Mab solution	10 mM phosphate (MAB vial) fill in vial)	145 mM NaCl, 10 % w/v Maltose; I131-Mab; 5–6% Povidone, 1–2, 9–15 mg/mL Maltose, 0.9 mg/mL NaCl, 0.9–1.3 mg/mL Ascorbic acid		7.2
3	Campath	Alentuzumab	Humanized, IgG1k, 150 kDa	2001	Ilex Oncology; Millennium and Berlex	IV infusion	B-cell chronic lymphocytic leukemia, CD32-antigen	30 mg/3 mL solution	3.5 mg/3 mL dibasic NaPhos, 0.6 mg/3 mL monobasic KPhos	24 mg/3 mL NaCl, 0.6 mg/3 mL KCl, 0.056 mg/3 mL Na2EDTA	0.3 mg/3 mL PSS0	6.8–7.4
4	CEA-Scan (Iyo)	Acritumab; Tc-99	Murine Fab, 50 kDa	1996	Immunomedics	IV injection or infusion	Imaging agent for colorectal cancer	1.25 mg/vial Lyophilized MAb. Reconstitute w 1 mL Saline w Tc99m	0.29 mg/vial Stannous chloride, potassium sodium tartrate tetrahydrate, NaAcetate.3H $_2\text{O}$, NaCl, glacial acetic acid, HCl	Sucrose		5.7
5	Erbix	Cetuximab	Chimeric human/mouse IgG1k, 152 kDa	2004	ImClone and BMS	IV infusion	Treatment of EGFR-expressing colorectal carcinoma	100 mg MAb in 50 mL, 2 mg/mL solution	1.88 mg/mL DibasicNaPhos $\cdot$ 7H $_2\text{O}$; 0.42 mg/mL MonobasicNaPhos $\cdot$ H $_2\text{O}$	8.48 mg/mL NaCl		7.0–7.4
6	Herceptin (Iyo)	Trastuzumab	Humanized IgG1k	1998	Genetech	IV infusion	Metastatic breast cancer whose tumor overexpress HER2 protein	440 mg/vial, 21 mg/mL after reconstitution	9.9 mg/20 mL L-HistidineHCl, 6.4 mg/20 mL L-Histidine	400 mg/20 mL α -Trehalose Dihydrate	1.8 mg/20 mL PS20	6
7	Humira	Adalimumab	Human IgG1k, 148 kDa	2002	CAT and Abbott	SC	RA patients not responding to DMARDs, Blocks TNF-alpha	40 mg/0.8 mL solution (50 mg/mL)	0.69 mg/0.8 mL Monobasic NaPhos $\cdot$ 2H $_2\text{O}$; 1.22 mg/0.8 mL DibasicNaPhos $\cdot$ 2H $_2\text{O}$; 0.24 mg/0.8 mL NaCitrate, 1.04 mg/0.8 mL Citric acid $\cdot$ H $_2\text{O}$	4.93 mg/0.8 mL NaCl; 9.6 mg/0.8 mL Mannitol	0.8 mg/0.8 mL PSS0	5.2
8	Lucentis	Ranibizumab	Humanized IgG1k fragment	2006	Genentech	Intravitreal injection	Age-related macular degeneration (wet)	10 mg/mL solution	10 mM HistidineHCl	10% α -Trehalose-Dihydrate	0.01% PS20	5.5

9	Mylotarg (lyo)	Gentuzumab ozogamicin	Humanized IgG4k conjugated with calicheamicin	2000	Celltech and Wyeth	IV infusion	Humanized Ab linked to calicheamicin for treatment of CD33 positive acute myeloid leukemia	5 mg protein- equivalent lyophilized powder/20-mL vial	Monobasic and dibasic NaPhosphate	Dextran 40, Sucrose, NaCl	
10	OncoScint	Satumomab pendetide	Murine IgG1k conjugated to GYK-DTPA	1992	Cytogen	IV injection	Imaging agent for colorectal and ovarian cancer	0.5 mg conjugate/mL solution (2 mL per vial)	Phosphate buffer saline		6.0
11	Orthodone OKT	Muromonab-CD3	Murine, IgG2a, 170 kDa	1986	Ortho Biotech	IV injection	Reversal of acute kidney transplant rejection (anti CD3- antigen)	1 mg/mL solution (1 mL per vial)	2.25 mg/5 mL monobasic NaPhos, 9.0 mg/5 mL dibasic NaPhos	43 mg/5 mL NaCl 1 mg/mL PS80	7 ± 0.5
12	ProstaScint	Indium-111 capromab pendetide	Murine IgG1k- conjugated to GYK-DTPA	1996	Cytogen	IV injection	Imaging agent for prostate cancer	0.5 mg conjugate/mL solution (1 mL per vial)	Phosphate buffer saline		5–7
13	Raptiva (lyo)	Efalizumab	Humanized IgG1k	2003	Xoma and Genentech	SC	Chronic moderate to severe plaque psoriasis, binds after reconstitution to CD11a subunit of LFA-1	150 mg MAb/vial; 125 mg/1.25 mL (100 mg/mL) after reconstitution with 1.3 mL SWFI	6.8 mg/vial L-HistidineHCl · H ₂ O, 4.3 mg/vial L-Histidine	123.2 mg/vial Sucrose 3 mg/vial PS20	6.2
14	Remicade (lyo)	Infliximab	Chimeric human/ murine MAb against TNFalpha (app. 30% murine, 70% corresponds to human IgG1 heavy chain and human kappa light chain constant regions)	1998	Centocor	IV infusion	RA and Crohn's disease (anti TNFalpha)	100 mg / 20-mL Vial, 10 mg/mL on reconstitution	2.2 mg/10 mL MonobasicNaPhos H ₂ O, 6.1 mg/10 mL DibasicNaPhos · 2H ₂ O	500 mg/10 mL Sucrose 0.5 mg/10 mL PS80	7.2
15	ReoPro	Abciximab	Fab. Chimeric human- murine, 48 kDa	1994	Centocor / Lilly	IV injection and infusion	Reduction of acute blood clot related complications	2 mg/mL solution	0.01 M NaPhosphate	0.15 M NaCl	0.001% (0.01 mg/ mL) PS80 7.2
16	Rituxan	Rituximab	Chimeric mouse/ human IgG1k with murine light and heavy chain variable region (Fab domain), 145 kDa	1997	IDEC and Genentech	IV infusion	NonHodgkin's lymphoma, (anti CD20-antigen)	10 mg/mL solution	7.35 mg/mL NaCitrate · 2H ₂ O	9 mg/mL NaCl	0.7 mg/mL PS80 6.5

(Continued)

Table 1. (Continued)

#	Brand name	Molecule	MAb	Year	Company	Route	Indication	MAB Conc	Buffer	Excipients	Surfactant	pH
17	Simulect (lyo)	Basiliximab	Chimeric IgG1k, 144 kDa	1998	Novartis	IV injection and infusion	Prevention of acute kidney transplant rejection, IL-2 receptor antagonist	10 mg and 20 mg/ vial, 4 mg/mL on reconstitution	3.61 mg, 7.21 mg Monobasic KPhos; 0.50 mg, 0.99 mg Na ₂ HPO ₄	0.8 mg, 1.61 mg NaCl; 10 mg, 20 mg Sucrose; 40 mg, 80 mg Mannitol; 20 mg 40 mg Glycine		
18	Synagis (lyo)	Palivizumab	Humanized IgG1k, CDR of murine MAb 1129, 148 kDa	1998	MedImmune	IM injection	Prevent replication of the Respiratory syncytial virus (RSV)	50 mg and 100 mg/ vial, 100 mg/mL on reconstitution	47 mM Histidine, 3.0 mM Glycine	5.6 % Mannitol		
19	Tysabri	Natalizumab	Humanized IgG4k	2004	Biogen IDEC	IV Infusion	MS relapse	300 mg/15 mL solution	17.0 mg MonobasicNa Phos, H ₂ O, 7.24 mg diBasicNaPhos · 7H ₂ O for 15 mL	123 mg/15 mL NaCl	3.0 mg/15 mL PS80	6.1
20	Vertuma	Nofetumomab	Murine Fab	1996	Boehringer Ingelheim and DuPont Merck	IV injection	Imaging agent for lung cancer	10 mg/mL solution	Phosphate buffer saline			?
21	Xolair (lyo)	Omalizumab	Humanized IgG1k, 149 kDa		Novartis and Tanox	SC	Asthma, inhibits binding of IgE to IgE receptor FCεRI	202.5 mg/vial, Deliver 150 mg/ 1.2 mL on reconstitution with 1.4 mL SWFI	2.8 mg LHistidineHCl, H ₂ O; 1.8 mg LHistidine	145.5 mg Sucrose	0.5 mg PS20	
22	Zenapax	Daclizumab	Humanized IgG1, 144 kDa	1997	Roche	IV infusion	Prophylaxis of acute organ rejection in patients receiving renal transplants. Inhibits IL-2 binding to the Tac subunit of IL-2 receptor complex	25 mg/5 mL MAb Solution	3.6 mg/mL MonobasicNa Phos, H ₂ O; 11 mg/mL DibasicNaPhos · 7H ₂ O	4.6 mg/mL NaCl	0.2 mg/mL PS80	6.9
23	Zevalin	Ibritumomab-Tiuxetan	Murine IgG1k-thiourea covalent linkage to Tiuxetan		IDEC	IV infusion	CD20 antigen. (Kit with Yttrium-90 induces cellular damage by beta emission)	3.2 mg/2 mL solution		09% NaCl		7.1

Development of commercially viable antibody pharmaceuticals has, however, not been straightforward. This is because the behavior of antibodies seems to vary, even though they have similar structures. In attempting to address some of the challenges in developing antibody therapeutics, Harris et al.⁵ reviewed the commercial-scale formulation and characterization of therapeutic recombinant antibodies. In a different review, antibody production and purification have been discussed.² Nevertheless, the overall instability and stabilization of antibody drug candidates have not been carefully examined in the literature. This article, not meant to be exhaustive, intends to review the structure and functions of antibodies, discuss their instabilities, and summarize the methods for stabilizing/formulating antibodies.

ANTIBODY STRUCTURE

Antibodies (immunoglobulins) are roughly Y-shaped molecules or combination of such molecules (Fig. 1). Their structures are divided into two regions—the variable (V) region (top of the Y) defining antigen-binding properties and the constant (C) region (stem of the Y), interacting with effector cells and molecules. Immunoglobulins can be divided into five different classes—IgA, IgD, IgE, IgM, and IgG based on their C regions, respectively designated as α , δ , ϵ , μ , and γ (five main heavy-chain classes).⁶ Most IgGs are monomers, but IgA and IgM are respectively, dimers and pentamers linked by J chains. IgGs are the most abundant, widely used for therapeutic purposes, and their structures will be discussed as antibody examples in detail.

Primary Structure

The structure of IgGs have been thoroughly reviewed.⁶ The features of the primary structure of antibodies include heavy and light chains, glycosylation, disulfide bond, and heterogeneity.

Heavy and Light Chains

IgGs contain two identical heavy (H, 50 kDa) and two identical light (L, 25 kDa) chains (Fig. 1). Therefore, the total molecular weight is approximately 150 kDa. There are several disulfide bonds linking the two heavy chains, linking the heavy and light chains, and residing inside the chains (also see next section). IgGs are further divided




Figure 1. Linear (upper panel) and steric (lower panel) structures of immunoglobulins (IgG).

into several subclasses—IgG1, IgG2, IgG3, and IgG4 (in order of relative abundance in human plasma), with different heavy chains, named γ 1, γ 2, γ 3, and γ 4, respectively. The structural differences among these subtypes are the number and location of interchain disulfide bonds and the length of the hinge region. The light chains consist of two types—lambda (λ) and kappa (κ). In mice, the average of κ to λ ratio is 20:1, whereas it is 2:1 in humans.⁶ The variable (V) regions of both chains cover approximately the first 110 amino acids, forming the antigen-binding (Fab) regions, whereas the remaining sequences are constant (C) regions, forming Fc (fragment crystallizable) regions for effector recognition and binding.⁶ The N-terminal sequences of both the heavy and light chains vary greatly between different antibodies. It was suggested that the conserved sequences in human IgG1 antibodies

are approximately 95% and the remaining 5% is variable and creates their antigen-binding specificity.⁵

The V regions are further divided into three hypervariable sequences (HV1, HV2, and HV3) on both H and L chains. In the light chains, these are roughly from residues 28 to 35, from 49 to 59, and from 92 to 103, respectively.⁶ Other regions are the framework regions (FR1, FR2, FR3, and FR4). The HV regions are also called the complementarity determining regions (CDR1, CDR2, and CDR3). While the framework regions form the β -sheets, the HV sequences form three loops at the outer edge of the β barrel (also see Section 2.2).

Disulfide Bonds

Most IgGs have four interchain disulfide bonds—two connecting the two H chains at the hinge region and the other two connecting the two L chains to the H chains.⁶ Exceptions do exist. Two disulfide bonds were found in IgG1 and IgG4 linking the two heavy chain in the hinge region but four in IgG2.⁷ In IgG1 MAb, HC is linked to the LC between the fifth Cys (C217) of HC and C213 on the LC. In IgG2 and IgG4 MAbs, it is the third Cys of HC (C123) linking to the LC.⁷ A disulfide bond between HC C128 and LC C214 was found for mouse catalytic monoclonal antibodies (IgG2a).⁸

IgGs have four intrachain disulfide bonds, residing in each domain of the H and L chains, stabilizing these domains. The intrachain disulfide bonds in V_H and V_L are required in functional antigen binding.⁹ Native IgG MAbs should not have any free sulfhydryl groups.⁷ However, detailed examination of the free sulfhydryl groups in recombinant MAbs (one IgG1, two IgG2, and one IgG4) suggests presence of a small portion of free sulfhydryl group (approximately 0.02 mol per mole of IgG2 or IgG4 MAb and 0.03 for IgG1.⁷ In rare cases, a free cysteine is found. A nondisulfide-bonded Cys at residue 105 was found on the heavy chain of a mouse monoclonal antibody, OKT3 (IgG2a).¹⁰

Oligosaccharides

There is one oligosaccharide chain in IgGs.⁶ This N-linked biantennary sugar chain resides mostly on the conserved Asn 297, which is buried between the C_H2 domains.^{5,11} For example, the oligosaccharide resides on Asn-297 of the C_H2 domain of chimeric IgG1 and IgG3 molecules¹²

but on Asn 299 in a monoclonal antibody, OKT3 (IgG2a).¹⁰ The oligosaccharide, often microheterogeneous, is typically fucosylated in antibodies produced in CHO or myeloma cell lines⁵ and may differ in other cell lines.^{2,11} There are many factors that dictate the nature of the glycan microheterogeneity on IgGs. These include cell line, the bioreactor conditions and the nature of the downstream processing. An additional oligosaccharide can be found in rare cases. A human IgG produced by a human-human-mouse heterohybridoma contains an additional oligosaccharide on Asn 75 in the variable region of its heavy chain.¹³ In addition, O-linked carbohydrates could also exist in this antibody.

Proper glycosylation is critical for correct functioning of antibodies.¹¹ It was demonstrated that removal of the oligosaccharide in IgGs (IgG1 and IgG3) made them ineffective in binding to C1q, in binding to the human $Fc\gamma RI$ and activating C; and generally more sensitive to most proteases than their corresponding wild-type IgGs (one exception).¹² This is because the binding site on IgG for C1q, the first component of the complement cascade, is localized in the C_H2 domains.¹¹ Furthermore, the glycosylation can affect the antibody conformation.¹²

Oligosaccharides in other regions can also play a critical role. Removal of an oligosaccharide in a Fv region of the CBGA1 antibody resulted in a decreased antigen-binding activity in several ELISA systems.¹³ In addition, this oligosaccharide might play critical role in reducing the antigenicity of the protein.¹⁴

The sugar composition of the oligosaccharide is also critical in antibody functions. It has been shown that a low fucose (Fuc) content in the complex-type oligosaccharide in a humanized chimeric IgG1 is responsible for a 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) compared with a high Fuc counterpart.¹⁵

Heterogeneity

Purified antibodies are heterogeneous in structure. This is true for all monoclonal antibodies (MAbs) due to differences in glycosylation patterns, instability during production, and terminal processing.⁵ For example, five charged isoforms were found in recombinant humanized monoclonal antibody HER2 as found by capillary isoelectric focusing (cIEF) and sodium dodecyl sulfate–capillary gel electrophoresis (SDS–CGE).¹⁶ Six separate bands were focused under

IEF for two mouse monoclonal antibodies IgG2a (κ) and IgG1 (κ).¹⁷ A mature monoclonal antibody, OKT3 (IgG2a), contain cyclized N-terminus (pyroglutamic acid, -17 D) in both H and L chains, processed C-terminus (no Lys, -128 D) of the H chains, and a small amount of deamidated form.¹⁰ Similar observation was also reported for a humanized IgG1 (κ).¹⁸ In rare cases, gene cross-over may lead to formation of abnormal heavy chains. For example, a purified monoclonal anti-IgE antibody contains a small amount of a variant H chain, which had 16 fewer amino acid residues than the normal H chain (position is between Arg108 of the L chain and Ala124 of the H chain).¹⁹

Secondary and Higher-Order Structure

The basic secondary and higher-order structural features of IgGs have been reviewed.⁶ Only a small portion of the three-dimensional structures of IgGs has been solved.²⁰ The antibody's secondary structure is formed as the polypeptide chains form anti-parallel β -sheets. The major type of secondary structure in IgGs is these β -sheets and its content is roughly 70% as measured by FTIR.²¹ The light chain consists of two and the heavy chain contains four domains, each about 110 amino acid long.^{6,20} All these domains have similar folded structures— β barrel, also called immunoglobulin fold, which is stabilized by a disulfide bond and hydrophobic interaction (primary). These individual domains (~ 12 kDa in size) interact with one another (V_H and V_L ; C_H1 and C_L ; and between two C_H3 domains except the carbohydrate-containing C_H2 domain) and fold into three equal-sized spherical shape linked by a flexible hinge region. These three spheres form a Y shape (mostly) and/or a T shape.²²

The less globular shape of IgGs is maintained both by disulfide bonds and by strong noncovalent interactions between the two heavy chains and between each of the heavy-chain/light-chain pairs.²³ Through noncovalent interactions, a less stable domain becomes more stable, and thus, the whole molecule can be stabilized.²⁴ A detailed study indicates that the interaction between two $CH3$ domains are dominated by six contact residues, five of these residues (T366, L368, F405, Y407, and K409) forming a patch at the center of the interface.²⁵ These noncovalent interactions are spatially oriented such that variable domain exchange (switching V_H and V_L ; inside-out IgG; ioIgG) induces noncovalent multimerization.²⁶

The six hypervariable regions in CDR (L1, L2, L3, H1, H2, and H3) form loops of a few predictable main-chain conformations (or canonical forms), except H3 loop, which has too many variations in conformation to be predicted accurately.^{27,28} There is a slight difference in the loop composition and shape between the two types of light chains.²⁰ However, no functional difference was found in antibodies having λ or κ chain.⁶

Basic Functions of Antibodies

The basic functions of antibodies have been reviewed.⁶ There are two functional areas in IgGs—the V and C regions. The V regions of the two heavy and light chains offer two identical antigen-binding sites. The binding of the two sites (bivalent) can be independent of each other and does not seem to depend on the C region.²⁹ The exact antigen-binding sites are the CDR regions with participation of the frame work regions.³⁰ Binding of antigens seems through the induced-fit mechanism.^{31,32} The induced-fit mechanism allows multispecificity and polyreactivity. It has been suggested that about 5–10 residues usually contribute significantly to the binding energy.³²

The C regions of antibodies have three main effector functions (1) being recognized by receptors on immune effector cells, initiating antibody-dependent cell cytotoxicities (ADCC), (2) binding to complement, helping to recruit activated phagocytes, and (3) being transported to a variety of places, such as tears and milk.⁶ In addition, C domains also modulate *in vivo* stability.^{23,29,33} The function of Fc is affected by the structure of Fab. Variable domain exchange (switching V_H and V_L ; inside-out IgG; ioIgG) affected Fc-associated functions such as serum half-life and binding to protein G and Fc γ RI.²⁶

The hinge region provides flexibility in bivalent antigen binding and activation of Fc effector functions.²⁶ Two chimeric IgG3 antibodies lacking a genetic hinge but with Cys residues in $CH2$ regions was found to be deficient in their intermolecular assembly, and both IgG3 $\Delta H + Cys$ and IgG3 $\Delta H + 2Cys$ lost greatly their ability to bind Fc γ RI and failed to bind C1q and activate the complement cascade.³⁴

Alternative Forms of Antibodies

In addition to species-specific antibodies, other antibody forms are generated to meet various needs. In the early development of antibody therapies, antibodies were made from murine

sources. However, these antibodies easily elicit formation of human anti-mouse antibody (HAMA). Therefore, humanized chimeric antibodies were generated. Chimeric monoclonal antibodies (60–70% human) are made of mouse variable regions and human constant regions.² Such antibodies can still induce formation of human anti-chimeric antibody (HACA). Highly humanized antibodies, CDR-grafted antibodies, are made by replacing only the human CDR with mouse CDR regions (90–95% human).² These antibodies are almost the same in immunogenicity potential as completely human antibodies, which may illicit formation of human anti-human antibody (HABA).

Other alternative forms of antibodies have also been generated and these different forms have been reviewed.³⁵ Treatment with papain would cleave the N-terminal side of the disulfide bonds and generate two identical Fab fragments and one Fc fragment. Fab's are 50 kDa ($V_H + C_H1$)/($V_L + C_L$) heterodimers linked by a single disulfide bond. Treatment with pepsin cleaves the C-terminal side of the disulfide bonds and produces a $F(ab')_2$ fragment. The remaining H chains were cut into several small fragments.⁶ Cleavage by papain occurs at the C-terminal side of His-H228³⁶ or His-H227.³⁷ Reduction of $F(ab')_2$ will produce two Fab'.²³

Fv fragments are noncovalent heterodimers of V_H and V_L . Stabilization of the fragment by a hydrophilic flexible peptide linker generates single-chain Fv (scFvs).² Fragments without constant domains can also be made into domain antibodies (dAbs). These scFvs are 25–30 kDa variable domain ($V_H + V_L$) dimers joined by polypeptide linkers of at least 12 residues. Shorter linkers (5–10 residues) do not allow pairing of the variable domains but allow association with another scFv form a bivalent dimer (diabody) (about 60 kDa, or trimer: triabody about 90 kDa).³⁸ Two diabodies can be further linked together to generate bispecific tandem diabody (tandab).³⁹ Disulfide-free scFv molecules are relatively stable and useful for intracellular applications of antibodies—"intrabodies."³⁸ The smallest of the antibody fragments is the minimal recognition unit (MRU) that can be derived from the peptide sequences of a single CDR.²

ANTIBODY INSTABILITY

Antibodies, like other proteins, are prone to a variety of physical and chemical degradation path-

ways, although antibodies, on the average, seem to be more stable than other proteins. Antibody instabilities can be observed in liquid, frozen, and lyophilized states. The glycosylation state of an antibody can significantly affect its degradation rate.⁴⁰ In many cases, multiple degradation pathways can occur at the same time and the degradation mechanism may change depending on the stress conditions.⁴¹ These degradation pathways are divided into two major categories—physical and chemical instabilities. This section will explore the possible degradation pathways of antibodies and their influencing factors.

Physical Instability

Antibodies can show physical instability via two major pathways—denaturation and aggregation.

Denaturation

Antibodies can denature under a variety of conditions. These conditions include temperature change, shear, and various processing steps. Compared with other proteins, antibodies seem to be more resistant to thermal stress. They may not melt completely until temperature is raised above 70°C,^{21,42,43} while most other mesophilic proteins seem to melt below 70°C.⁴⁴ Shear may cause antibody denaturation. For example, the antigen-binding activity of a recombinant scFv antibody fragment was reduced with a first-order rate constant of 0.83/h in a buffer solution at a shear of approximately 20,000/s.⁴⁵

Lyophilization can denature a protein to various extents. An anti-idiotypic antibody (MMA 383) in a formulation containing mannitol, saccharose, NaCl, and phosphate was found to lose its *in vivo* immunogenic properties (only 10–20% of normal response rate) upon lyophilization.⁴⁶ Since the protein showed no evidence of degradation after lyophilization, no change in secondary structure by CD (29% β -sheet, 14% α -helix, and 57% "other"), the loss of activity was attributed to the conformational change. Indeed, tryptophan fluorescence properties were different between the lyophilized and unlyophilized antibodies.⁴⁶

Aggregation

Antibody aggregation is a more common manifestation of physical instability. The concentration-dependent antibody aggregation was considered the greatest challenge to developing protein formulations at higher concentrations.⁴⁷ This is

because protein aggregates generally have reduced activity and more importantly, greater immunogenicity potential because of the multiplicity of epitopes and/or conformational changes.^{14,48} Immunoglobulin aggregates have been shown to cause serious renal failure⁴⁹ and anaphylactoid reactions such as headache, fever, and chills.⁵⁰ Therefore, the aggregate level in commercial intravenous immunoglobulin products is limited to less than 5% based on the WHO standards.

Aggregates can form easily both in liquid and solid states under a variety of conditions (Tab. 2). Since protein aggregation is often the consequence of protein–protein interactions, a process influenced by diffusion rate and geometric constraints of the interaction sites, such factors would influence significantly the aggregation rate, including protein concentration change, viscosity, ionic strength, pH, and temperature.⁵¹ Other conditions may also affect protein aggregation, including shaking, long-term storage, freeze-thaw process, lyophilization process, etc.

Increasing the concentration of antibodies often increases the aggregation tendency of the protein. It was demonstrated that increasing the IgG1 concentration (in 10 mM citric acid, 100 mM NaCl pH 5.5) from 2.7 mg/mL to 50 mg/mL almost linearly increased the Nephelometric Unit (NU) from 2 to 40.⁵² Since EP defines a clear solution as having equal or less than three NU, most antibody solutions in the study are opalescent except those at 5 mg/mL or less. However, as the weight average molecular weight was found to be 0.9–1.3 times that expected of a monomer (about 149 kDa), minimal protein–protein association (and readily reversible) is suggested.⁵² Shaking can accelerate antibody precipitation and the shape of the precipitates may depend on the sample volume in a container.⁵³ It appears that protein solutions exhibiting lower surface tension are more susceptible to protein denaturation and precipitation.⁵³

Low-temperature treatment may induce aggregation of antibodies. The reversible low-temperature-induced aggregation (below 37°C) of serum cryoglobulins is well known.⁵⁴ Human IgM cryoglobulin preparations easily precipitate or gel at temperatures below 10–12°C and the process is reversible at a higher temperature.²⁰ In a recent study, aggregation of IgG1 at low temperature at above 18 mg/mL was reversible as measured by light scattering.⁵² The low-temperature-induced aggregation of cryoglobulins is poorly understood and was thought to involve sites within both Fab

and Fc.²⁰ The authors of this article believe that low temperature reduces the hydrophobic interaction, which is the major force in protein folding. Without enough hydrophobic interaction at low temperature, hydrophobic regions of antibodies become more exposed to solvent and lead to increased intermolecular hydrophobic interaction, leading to aggregation.

In close relation to the low-temperature effect, freeze-thaw process often induces protein aggregation. However, freeze-thaw-induced antibody aggregation does not seem to be a major issue, partly due to the reversibility of antibody aggregates. Freeze-thawing of a chimeric (L6) antibody solution at pH 7.2 for as many as 35 times led to formation of dimers (not larger aggregates).⁴¹ Maximum amount of dimers (about 20%) was observed at pH 6.5 and minimum was below 5.5 or above 8.5 (less than 2%). The freeze-thaw-induced aggregation is apparently reversible after treatment at 37°C for a few hours.⁴¹ Freeze-thawing of rhuMAb anti-CD20 three times (freezing to either –20 or –70°C, thawing to 5°C) did not lead to significant change in aggregation, no significant loss of monomer by RP-HPLC or SEC-HPLC.⁵⁵ On the other hand, isolated Fabs seems to be more prone to freeze-thaw-induced aggregation relative to full-length antibodies. For example, Lee⁵⁶ found that freeze-thawing of a scF_v (MW 27,000 d) at 1.45 mg/mL in sodium phosphate buffered saline (PBS) at pH 7.3 dropped the %monomer content (due to aggregation) from 95% to 84%, 59%, 44%, and 37%, respectively after 1–4 cycles.

Lyophilization may induce antibody aggregation to a variable degree. It was demonstrated that lyophilization of a recombinant humanized monoclonal antibody (rhuMAb HER2), in the absence of sugars, led to a slight increase in aggregate (less than 1.2%).⁵⁷ Lyophilization caused detectable aggregation of a human monoclonal antibody in PBS or physiological saline as measured by OD600,⁵⁸ and aggregation of a mouse monoclonal antibody (MN12) [IgG2a (κ)] in the absence or presence of 5% sucrose, dextran, or hydroxypropyl-beta-cyclodextrin (HP-β-CD), as measured by visual examination.⁵⁹ In a different study, lyophilization of a monoclonal antibody-vinca conjugate in PBS at pH 7.4 caused 6.2% aggregation.⁶⁰ The lyophilization-induced aggregates could be non-covalent-linked monomers and/or even disulfide-linked.^{61,62}

Antibody aggregation can easily occur during storage in a liquid state. Storing of a fully human anti-IL8 monoclonal antibody (ABX-IL8; IgG2)

Table 2. Instabilities of Antibodies

Instability	Antibody	Formulation	Condition	Effect	References
Denaturation	scFv	3 µg/mL in 10 mM phosphate-buffered saline containing 0.02% sodium azide	Shaking at a mean velocity gradient approximately 20,000/s	Loss of activity at a first-order rate of 0.83/h	45
Aggregation	Chimeric mouse/human IgG1	2 mg/mL in PBS at pH 7.2	Stirring for 48 h with Teflon bar at 600 RPM	Increased turbidity	91
	Human Anti-IL-8 (IgG2)	55 mg/mL, 5 mM His, pH 6	Freeze/thaw three times (room/−70°C)	Formation of >15 k particles (>10 µ)	21
	Anti-IL-8 (IgG2)	100 mg/mL, 200 mM Sucrose, 15 mM Arg, 15 mM His, pH 6	Incubation at 40°C for 6 months	About 0.6% aggregates (by SEC-HPLC)	21
	rhuMAbE25	10 mg/mL in excipient-free solution	Spray drying Tin = 105°C, Tout = 50–55°C	About 11% aggregates (by SEC-HPLC)	65
	MAB (type not specified)	MAB at 40 mg/mL, 85 mM sucrose, 5 mM His at pH 6, 0.01% Tween 20	Lyophilization	5–6% aggregate (by SEC-HPLC)	1
Deamidation	Human Anti-IL-8 (IgG2)	50 mg/mL, 20 mM Gly, 4 mM His, 0.2% mannitol, 16 mM Glu, 0.03% Tween 20 pH 5.7	Incubation of lyophilized form at 37°C for 1 month	Cloudy (OD350 > 0.2)	21
	RhuMAb HER2	50 mg/mL in 100 mM trehalose, 5 mM His at pH 6.0	Incubation of lyophilized form at 40°C for 23 months	4.8% aggregates (by SEC-HPLC)	57
	OKT3 (IgG2a)	1 mg/mL, PBS at pH 7.0 + Tween80	Incubation at 37°C for 2 months	9.7% aggregates (by SEC-HPLC)	10
Isomerization	LA298 (IgG1)	0.5 mg/mL in 10 mM citrate at pH 7	Incubation at 25°C for 6 weeks	90% deamidation of Asn386 ~12% increase in deamidation at Asn55	78
	MAB	Lyophilized at 40 mg/mL, 85 mM sucrose, 5 mM His, 0.01% Tween 20, pH 6.0, containing 8.4% moisture	Incubation at 5°C	First-order rate constant ~ 0.33 × 10 ^{−4} /day	1
Oxidation	rhuMAb HER2	5 mg/mL, 147 mM NaCl, 0.01% polysorbate 20, 5 mM sodium acetate at pH 5.0	5, 30, and 40°C for 2 weeks	10, 17, and 52% (total peak area)	81

in aqueous solutions at 2–8°C or 25°C led to formation of high-molecular-weight (HMW) species.²¹ Incubation of two mouse monoclonal antibodies IgG2a (κ) and IgG1 (κ) at 37°C for 32 days caused precipitation in pH 3 and 4 solutions for both antibodies.¹⁷ Aggregation can also occur to an antibody conjugate. Storing a monoclonal antibody-vinca alkaloid conjugate (murine IgG2a) in phosphate-buffered saline solutions at 5°C between pH 4.5 and 7.4 for 1.5 months caused precipitation regardless of solution pH and aggregation was accelerated at 30°C throughout the pH range.⁶³

Antibody aggregation is a common phenomenon during storage in a lyophilized state. Aggregation ($OD_{350} > 0.2$) was observed of a high concentration, lyophilized, monoclonal antibody (type not specified) by SEC under accelerated conditions.¹ So did a lyophilized chimeric monoclonal antibody during storage at 5°C (0.4% after 2 months).⁶⁴ In the absence of sugars, the extent of rhuMAb HER2 aggregation increased from about 1% to >10% after 3 months at 40°C and the rate of aggregation for these formulations was about 0.2% per month at 40°C.⁵⁷

Antibody aggregation can readily occur in other solid forms during storage.⁵ It was found that the primary degradation upon storage of a spray-dried anti-IgE (protein:mannitol = 80:20) is aggregation, and the amount of aggregates increased with increasing temperature and relative humidity (Maa et al., 1998a).⁶⁵ As much as 52% aggregate was observed by SEC-HPLC of a spray-dried anti-IgE (protein:mannitol = 80:20) after 1 year at 40°C and 38% RH (Maa et al., 1998b).⁶⁶

Antibody aggregation is usually accelerated upon thermal treatment. In the study of chimeric (human/mouse) monoclonal antibody (BR96), Alexander and Hughes demonstrated that thermal treatment at 60°C for 166 h generated noncovalently linked aggregates.⁶⁷ In the evaluation of the relative stability of murine IgG2a (κ), chimeric IgG1(κ), trioma IgG1 (λ), and murine IgG1 (κ), Hartmann et al. demonstrated that IgG2a (κ) aggregated and precipitated after heating at 55°C for 8 h and the half-life for the loss of monomer for those four IgGs is 1, 18.1, 3.4, and 8.2 h with different aggregate species (dimer, trimer...) by SEC-HPLC.⁶⁸

Surface Adsorption

Antibodies, like other proteins, can easily adsorb to a variety of surfaces. Surface adsorption can

significantly reduce the antibody concentration in a solution. For example, a mouse monoclonal IgG1 has been shown to be adsorbed on the surface of glass shake flasks, causing a loss of protein in plant culture media.⁶⁹ Such a loss was minimized by coating the glass vessels or by addition of Pluronic F127.

Chemical Instability

A variety of chemical degradation pathways have been observed. These chemical degradants may or may not lose protein activity depending on the site of changes. For examples, deamidation of a monoclonal antibody, OKT3 (IgG2a) as measured by change in IEF pattern does not correlate with loss of antigen binding potency (90% deamidation of Asn386 vs. 80% activity in the potency assay).¹⁰ In comparison, the activity of light chain deamidated recombinant humanized monoclonal antibody HER2 (rhuMAb HER2, Herceptin, trastuzumAb) at Asn30 (to aspartate) is only 70% of the main species and that of the isomerized (heavy chain) asp102 species is only 9–21% of major species.³⁷ The major chemical degradation pathways in an antibody include cross-linking, deamidation, isomerization, oxidation, and fragmentation.

Disulfide Formation/Exchange

Disulfide bond formation/exchange is probably the most common cross-linking pathway, leading to chemical aggregation. This degradation pathway can occur readily in various processing steps. For example, lyophilization of a murine monoclonal antibody (IgG2a) without additives reduced the average number of –SH groups per molecule from 6.65 to 6.28, suggesting disulfide formation.⁷⁰ Since the thiolate ions are often the initiating species for this chemical degradation, increasing formulation pH usually leads to increased formation of disulfide formation. This is the case for an antifebrin T2G1s Fab' (IgG1 (κ)), containing free –SH groups, where the percentage of dimers increased with increasing the pH from 5.8 to 9.5.⁶¹

Storage often leads to disulfide-based aggregation. Storage of a lyophilized excipient-free antibody (IgG1, containing 12 intra and 4 interchain disulfides) formulation for 1 year at 30°C resulted in formation of reducible dimer and trimers.⁶² Similarly, reducible aggregates of a monoclonal antibody (type not specified) were detectable

by SDS-PAGE after storage of the lyophilized formulation at 50°C for 6 months.¹ Such disulfide-linked covalent dimers and trimers were also observed during storage of spray-dried anti-IgE humanized monoclonal antibody.⁷¹

Nonreducible Cross-Linking

Nonreducible cross-linking was observed in several studies. Incubation of a human monoclonal antibody (C23) in solution at a basic pH at 37°C for 14 days resulted in formation of nonreducible bands above the light chains at pH 4 and 10.⁷² Incubation of two mouse monoclonal antibodies—IgG2a (κ) and IgG1 (κ), between pH 3.0 and 10 at 37°C for 32 days led to formation of a nonreducible 88 kDa species by SDS-PAGE.¹⁷ A species with the same molecular weight was observed after incubation of another monoclonal antibody, OKT3 (IgG2a), at 37°C for 2 months.^{10,73} Further examination suggests that this species is a cross-linked product of H and L chains between the L46-52 and H99-121 regions. Although the exact chemical nature was not determined, an oxidative step is apparently involved as inhibition of oxidation delayed the formation of this species.^{10,73}

A recent study shows that a nonreducible thioether bond can be formed between C223 of the heavy chain and the C-terminal Cys residue of the light chain in humanized IgG1 antibodies. This cross-linked product has a molecular weight of 75 kDa by MS but shows an apparent molecular weight of 92 kDa by SDS-PAGE.⁷⁴

Nonreducible cross-linked products were also observed in solid dosage forms. Incubation of a lyophilized mouse monoclonal antibody [IgG2a (κ)] without lyoprotectant or in the presence of 5% sucrose, dextran, or hydroxypropyl-beta-cyclodextrin (HP- β -CD) at 56°C for 18 days led to formation of 100-kDa band under reduced conditions by SDS-PAGE.⁵⁹

Deamidation

Antibody deamidation has been extensively reported in the literature. This common protein degradation pathway is so prevalent that purified antibody preparations may contain many deamidated forms. For example, several deamidated forms of recombinant humanized monoclonal antibody HER2 (rhuMAb HER2, Herceptin, trastuzumAb) were found by cation-exchange chromatography, including (1) deamidated Asn30 (to aspartate) on one light chain, (2) deamidated

Asn30 (to aspartate) on two light chains, and (3) deamidated Asn55 on the heavy chain (to iso-aspartate).³⁷ The sole conversion of Asn30 to aspartate (not isoaspartate) suggests that the deamidation mechanism in cell culture may be different from that during storage.

Storage can easily generate large amounts of deamidated products. Incubation of a monoclonal antibody, OKT3 (IgG2a) in a PBS solution at pH 7 containing Tween 80 at 37°C for 2 months led to more than 90% deamidation at Asn H386.¹⁰ By monitoring the ammonia generation, Poborji et al.⁴¹ estimated that 4% of the total number of Asn and Gln residues in a chimeric antibody (L6) was deamidated after storing the solution at pH 7.2 at 50°C for 3 weeks.

Deamidation also occurs in solid state. In the evaluation of storage stability of a model recombinant humanized monoclonal antibody (rhuMAb HER2), Cleland et al. reported that incubation of a high-moisture formulation (8.4% moisture) for 12 months at 40°C resulted in a 19% drop in the main peak by IEX due to deamidation.⁵⁷

Deamidation in proteins goes mostly through the intermediate of succinimide at Asn (more readily) and Gln (see reviews^{75,76}). This seems to be the case for antibodies, even though alternative mechanisms were reported, such as deamidation of Asn30 on the light chain of recombinant humanized monoclonal antibody HER2 (rhuMAb HER2, Herceptin, trastuzumAb).³⁷ A method has been developed to detect the formation of succinimide.⁷⁷

The rate of deamidation via succinimidation in proteins can be affected by a variety of factors, such as pH, sequence, and steric effect (see review⁴⁴). A recent report demonstrated a strong pH-dependency of deamidation at Asn55 (pH 7 > pH 6 > pH 5 > pH 4) in a fully human IgG1 in the pH range of 4–7 during storage at 25°C.⁷⁸ Using small peptide as a model, Tyler-Cross and Schirch⁷⁹ found that deamidation of Asn residues depends on the amino acid residue on the carboxyl side of Asn in neutral and alkaline solutions. Increasing the size and branching of these amino acids decreased the rate of deamidation by as much as 70-fold compared with the N-G sequence (greatest rate of deamidation) but under acidic conditions, these amino acids lost their protective effect.

Isomerization

The most common isomerization in antibodies is iso-aspartic acid formation, which results not only

from direct isomerization of Asp but also, mostly, from hydrolysis of succinimide intermediate. The pH-dependent formation of succinimide intermediate can occur either from Asn deamidation or Asp dehydration.³⁶ In neutral and alkaline condition, the isoAsp and Asp products formed in a peptide were at a ratio of about 3:1.⁷⁹

Isomerization is also prevalent and difficult to control. Again, many purified proteins contain significant amount of isomerized products, either from deamidation or direct isomerization. A typical example is recombinant humanized monoclonal antibody HER2 (rhuMAb HER2, Herceptin, trastuzumAb).³⁷ In addition, since isomerization occurred at Asp H102 in CDR regions, the activity of the isomerized species is only 9–21% of the major species.³⁷ Similarly, isomerization of Asp L32 on one light chain in a recombinant monoclonal anti-IgE antibody (E25) reduced the relative binding activity of F(ab')₂ to 42% and the activity of isomerized form on both chains (iso-Asp-iso-Asp) to 15%.³⁶

Since formation of the succinimide intermediate does not need participation of water, it can readily occur in solid state. Asp isomerization is one of the major degradation pathways for a lyophilized, monoclonal antibody (type not specified), and increases with increasing storage temperatures both above and below their T_g values.¹

Like deamidation, the relative rate of isomerization can be influenced strongly by steric effect. For example, a recombinant monoclonal anti-IgE antibody (E25) contains two Asp-Gly sequences within its CDRs, but only one site was found to be labile to isomerization (Asp L32). The unreactivity of one Asp residue is suggested to be due to hydrogen bonding.³⁶

Oxidation

The oxidizable residues in proteins include Met, Tyr, Trp, His, and Cys. Although oxidation is not as prevalent as deamidation and isomerization in antibodies, it can easily occur during storage of antibodies. For example, the major route of degradation of a monoclonal antibody, OKT3 (IgG2a), in solution during storage at 5°C is oxidation of a nondisulfide Cys and several Met residues.¹⁰ Oxidation was also observed in rhuMAb anti-CD20 in solution during storage at 40°C for 2 months.⁵⁵

Oxidation of CDP870, a pegylated one-half antibody (one light and one heavy chain) at a Met residue (M3) was also observed after incubation of

the protein at 25°C or 40°C for 12 weeks (14% at pH 4.1 and 4.2% at pH 5.5).⁸⁰ Light exposure can accelerate baseline oxidation. For example, light exposure (20,000 lux for 2 weeks at 27°C) of recombinant humanized monoclonal antibody HER2, rhuMAb HER2 caused 5–10% increase in oxidation in various liquid formulations at Met H255 (primary site) and Met H431 at temperatures 30 and 40°C.⁸¹

Formation of Acidic or Basic Species

Antibodies can form acidic or basic species, which are often monitored by IEF or ion exchange chromatography. Among all the possibilities, deamidation is the most likely degradation pathway, leading to formation of acidic species. Therefore, formation of such species is used loosely as an indication of deamidation in the absence of other confirmatory studies. Strictly speaking, formation of such species can only be considered as an indication of chemical instability (see below). A pH-dependency is almost certain for this kind of degradation. In the stabilization of CDP870, a one-half antibody (one light and one heavy chain), which is linked through Cys to a branched (20 kDa each) PEG, Johnson et al.⁸⁰ found that the protein generated more acidic species (up to 17% at pH 4.1 and 41% at pH 5.5) by IEF as the solution pH was increased from 4.1, 4.5, 5.0, to 5.5 during storage at 25°C for 12 weeks.⁸⁰

Another possible mechanism for generating acidic species in antibodies is the Maillard reaction, where reducing sugars can react with lysine residues. Such a reaction will result in loss of positive charges and formation of apparently more acidic species. This is the case for an spray-dried anti-IgE humanized monoclonal antibody with lactose during storage.⁷¹

Formation of basic species was also observed in antibodies. Its formation can result from several possibilities, most likely as a result of succinimide formation, removal of sialic acids, or pyroGlu formation. Such a basic species was observed after incubation of a human monoclonal antibody (C23) at 37°C for 14 days in a solution at an acidic pH by IEF.⁷²

C-Terminal Clipping

Terminal cleavages can easily occur during normal production of antibodies. For example, the majority of a purified chimeric protein rCD4-IgG lacks the heavy chain C-terminal Lys.⁸²

This is also the case for recombinant humanized monoclonal antibody HER2 (rhuMAb HER2, Herceptin, trastuzuMAb)³⁷ and a recombinant monoclonal anti-IgE antibody (E25).³⁶ It was suggested that the cleavage was due to the action of basic carboxypeptidases during production.³⁷

Fragmentation

The most likely sequences leading to fragmentation in proteins are Asp-Gly and Asp-Pro,⁸³ although other sequences can also experience cleavages, such as Asn-Ser.⁷⁹ Fragmentation can easily occur in antibodies even during production processes. A small amount of fragment (MW < LC) was detectable under reduced condition in a purified recombinant MAb IgG4 produced in Chinese hamster ovary (CHO) cells.⁷ Half molecules should be monitored routinely for IgG4s.⁸⁴

A variety of processing conditions may accelerate fragmentation of antibodies, such as acidic or basic treatment,⁷² thermal treatment,^{41,67} freeze-thaw,⁴¹ and storage.^{17,73,78} Fragments can simply include masses with a loss of a light chain (M-LC), a loss of a Fab arm (M-Fab), and separated heavy-chain (HC) and light-chain (LC), as well as species less than common antibody subunits, resulting from both peptide and/or disulfide bond cleavage.⁶⁷ Antibodies are also subject to radiation-induced cleavages.⁸⁵

Maillard Reaction

Proteins may form adducts with sugars. In an investigative study, mouse MAbs were found to form glucose adducts after incubation with 0.5 M glucose at pH 7.4 for 14–21 days at 37°C and the glycated antibodies significantly increased the dissociation of the antibody-antigen binding complex.⁸⁶

ANTIBODY FORMULATION

As mentioned above, antibodies, like other proteins, may generate a variety of degradants during production, processing, and storage both in liquid and solid states. Their tendency to generate such degradants depends very much on their individual sequence, pI, hydrophobicity, and carbohydrate content.²³ The antibody degradation products may have reduced activity and more importantly, increased immunogenicity.^{14,87} A strong immune response (antibody formation)

may lead to severe neutralization of the protein drug product and even endogenous proteins.

The major purpose of formulating antibodies as therapeutic agents is to control the rate of antibody degradation to provide an acceptable shelf life for worldwide shipping and storage. This can be done by choosing proper formulation excipients and other formulation conditions. It should be stressed that one formulation excipient stabilizing a specific antibody may not be suitable for another because of the differences in their sequence. A proper formulation composition should not only maximally preserve the activity of the antibody but also minimize the potential immune response, as excipients could alter the immune response by changing the presentation of the protein (such as the spacing of epitopes).¹⁴ The following section will discuss critical factors in formulating both liquid and lyophilized antibody products. Advanced formulations will also be briefly described.

Liquid Formulation

Liquid dosage form is usually preferable to lyophilized products as it is easier to administer and less expensive to manufacture. Among all the commercial antibody products, about half are stable enough to be formulated in a liquid form (Tab. 1). Formulating a successful liquid product needs consideration of at least the following aspects.

Protein Concentration

Since the EC50 values of antibodies are often 10–1,000 times higher than for other proteins such as hormones and cytokines,³⁵ a relatively large amount of antibodies needs to be dosed to achieve any therapeutic effect. A large dose requires that an antibody product needs to be formulated/reconstituted at a high concentration to reduce dose volume, especially for subcutaneous injections; otherwise, a large volume of antibody preparation has to be infused. Since the aggregation process is usually concentration-dependent, antibodies at high concentrations have at least two potential issues: high tendency to aggregate during storage and likely high viscosity, leading to more difficulty during injection (injection time correlated with viscosity).⁴⁷ It has been suggested that the concentration-dependent protein aggregation is the greatest challenge to developing high-concentration

protein formulations.⁴⁷ On the other hand, moderate increase in protein concentration may not have a significant effect. In fact, increasing the concentration of antifebrin T2G1s Fab' (IgG1 (κ)), from 0.05 to 5.0 mg/mL in solution resulted in a decrease in dimer formation during storage (73.2% to 22.9% after 13 weeks at 22°C).⁶¹

An effective way to reduce the viscosity of an antibody solution is to add sufficient amount of NaCl.^{5,88} Adjustment of formulation pH could potentially reduce the viscosity of an antibody solution.⁸⁸ Although not very effective, histidine has been shown to reduce the solution viscosity of a fully human anti-IL8 monoclonal antibody (ABX-IL8; IgG2) from 20 to about 9 centistokes when its concentration was increased from 0 to 60 mM.²¹ However, use of such excipients in reducing viscosity can be limited, as the excipient can adversely affect the stability of the antibody, such as MAb anti-CD20.⁵⁵

Another potential issue in formulating high-concentration antibody products is their solubility limits, as presence of undissolved proteins are generally not acceptable for intravenous injection. Fortunately, the solubility of antibodies seems to be relatively high and solubility-limited formulation difficulty has rarely been reported to our knowledge. To increase the solubility of antibodies, excipients such as surfactants may be used. In a recent report, Golovanov⁸⁹ found that a combination of L-Arg and L-Glu at an equimolar concentration (50 mM) significantly increased the solubility of several proteins (either alone does not have a significant effect). In addition, the room-temperature storage stability (fragmentation) of proteins was significantly improved as monitored by SDS-PAGE.

One potential advantage of formulating a protein product at higher concentrations is the greater freeze-thaw stability. Often, proteins at high concentrations are more resistant to freeze-thaw-induced aggregation, as the interface-induced protein denaturation can easily reach a saturation point. However, it does not seem to be the case for antibodies. Increasing the concentration of a chimeric antibody (L6) did not inhibit freeze-thaw-induced aggregation.⁴¹ In addition, surfactants such as Pluronic F68 and Tween 80 did not appreciably prevent antibody aggregation. In a different study, Tween 80 alone (or Pluronic F68) at 0.1% failed to offer any protection against freeze-thaw-induced aggregation of a single-chain antigen-binding protein CC49/218 sF_v (MW 27,000 d) at 1.45 mg/mL in sodium PBS at

pH 7.3.⁵⁶ These results suggest that freeze-thaw-induced antibody aggregation may not be a surface phenomenon.

Effect of Formulation pH

Formulation development often starts with determination of a stable formulation pH. Like other proteins, the pH effect on the stability of antibodies depends on the formulation composition,⁵⁵ stress conditions,⁴¹ and even antibody concentration.⁸⁴ Formulation pH may affect the physical stability of antibodies as it alters the number and distribution of charges on the protein surface. For example, low pH (below 3) caused a loss of tertiary structure in rhuMAb anti-CD20.⁵⁵ Low pH (pH 3 and 4) is also responsible for the precipitation of two mouse monoclonal antibodies IgG2a (κ) and IgG1 (κ) during incubation at 37°C for 32 days.¹⁷ Susceptibility to pH stress varies among different IgG molecules.⁶⁸

Regarding chemical stability, formulation pH may play a critical role in controlling many degradation pathways, such as disulfide bond formation/exchange, deamidation, fragmentation, isomerization, etc. Due to variable effects on different degradation pathways, the optimum pH value varies depending on both the sequence of an antibody and the analytical methods used in monitoring the stability. By IEF, Lam et al. found that rhuMAb anti-CD20 is most stable at pH 5 within the pH range of 3–6 irrespective of protein concentration in formulations containing 10 mM citrate, 8% trehalose, and 0.05% Tween 20.⁵⁵ By SEC-HPLC, Usami et al. found that pH 6 was the most stable condition during incubation of a human monoclonal antibody (C23) at 37°C for 14 days in a solution containing isotonic sodium chloride between pH 4 and 10.⁷² Sometimes, the optimum pH values reside outside a certain range. In the study of the stability of a chimeric antibody (L6), minimum amount of dimer formation was observed at pH below 5.5 or above 8.5 (less than 2%) during freeze-thaw.⁴¹

It needs to be mentioned that oxidation could be inhibited by adjusting formulation pH. In a formulation containing 40 mg/mL MAb anti-CD20, 150 mM trehalose, 0.9% benzyl alcohol, 0.02% Tween 20, and 50 mM histidine, reducing the pH from 7.5 to 5 virtually eliminated the oxidation during storage at 40°C for 2 months.⁵⁵ In a different study, oxidation (M3) of PEG-CDP870, a one-half antibody, in a formulation containing 160 mg/mL CDP870, 10 mM sodium acetate, and

125 mM NaCl was slower at pH 5.5 than at pH 4.1 (4.2% vs. 14% after 12 weeks at 40°C).⁸⁰

Due to the simultaneous presence of multiple antibody degradation pathways, the formulation pH has to be adjusted to balance all the potential degradations. Generally, a weakly acidic condition seems to be the optimum for most antibodies (see Tab. 1).

Effect of Buffering Agents

It has been long recognized that both the type and concentration of a buffering agent may affect the stability of proteins (see review⁴⁴). For example, phosphate buffer accelerated deamidation of an IgG1 relative to citrate buffer at both pH 6.5 and 7.0 during storage at 25°C.⁷⁸ Therefore, proper choice of a buffering agent can potentially achieve both pH control and stabilization of antibodies. In rare cases, a buffering agent good for one antibody may be harmful to another. One of these agents is histidine, which has a pKa of pH 6 and potentially good in controlling a weakly acidic condition. It has been shown to provide better protection against precipitation for a fully human anti-IL8 monoclonal antibody (ABX-IL8; IgG2) upon thermal incubation both at 50 and 40°C than citrate at pH 6.²¹ Addition of a small amount of histidine (0.4 mM) also increased the freeze-thaw (4×) recovery of a single-chain antigen-binding protein CC49/218 sF_v (MW 27,000 d) at 1.45 mg/rnL in PBS solution at pH 7.3 from 37% to 90%.⁵⁶ On the contrary, histidine was found not only to increase the rate of aggregation of rhuMAb anti-CD20 during storage but also to induce coloration of the solution compared to a acetate-buffered antibody solution at pH 5.⁵⁵ In addition, oxidation of Fc was also faster in histidine solution.

The concentration effect of a buffering agent was demonstrated in a study where freeze-thaw-induced aggregation of a chimeric antibody (L6) was higher with increasing phosphate buffer concentration (0.01 vs. 0.05).⁴¹ Therefore, both the type and concentration of buffering agents need to be examined.

Effect of Formulation Excipients

Use of formulation excipients remains a major and convenient approach in stabilizing antibodies in solutions. It is so at least in reducing antibody aggregation.⁴⁷ A variety of formulation excipients have been shown to stabilize antibodies under different processing conditions and during sto-

rage, including sugars,⁴¹ polyols,⁴¹ amino acids,^{41,84} surfactants,⁸⁴ and polymers.^{45,84}

Formulation excipients are effective generally in protecting the physical stability of an antibody. Among these excipients, sugars are the most commonly used. A variety of sugars, such as sucrose, trehalose, glucose, have been shown to reduce the freeze/thaw-induced aggregation of rhuMAb anti-CD20,⁵⁵ a chimeric antibody (L6),⁴¹ a human anti-IL8 monoclonal antibody (ABX-IL8; IgG2),²¹ and a single-chain antigen-binding protein CC49/218 sF_v (27 kDa).⁵⁶ Other excipients can be equally or even more effective in protecting antibodies. Histidine was shown to be equally effective as sucrose in reducing freeze-thaw induced aggregation of a human anti-IL8 monoclonal antibody (ABX-IL8; IgG2) and combination with Arg resulted in a better protection than sucrose in solution stability at different incubation temperatures.²¹ Sugars are not always effective. In the evaluation of freeze-thaw stability of a single-chain antigen-binding protein CC49/218 sF_v (MW 27 kDa) at 1.45 mg/mL in sodium phosphate buffered saline (PBS) at pH 7.3, addition of 10 mM trehalose, lactose, glucose, or mannitol did not offer any protection.⁵⁶ In a rare case, sucrose has been shown to promote agitation-induced aggregation of an IgG1 antibody.⁹⁰

Formulation excipients may inhibit chemical degradation of antibodies. Replacing 0.14 M NaCl with 8% trehalose or 4% mannitol in a rhuMAb anti-CD20 increased the chemical stability as measured by IEX during storage at 40°C.⁵⁵ Such an effect is likely a result of stabilization of antibody conformation. Some excipients may protect antibodies against oxidation. Replacing NaCl with 4% mannitol and 1% benzyl alcohol protected recombinant humanized monoclonal antibody HER2, rhuMAb HER2, against oxidation (primarily Met-255) at 30 or 40°C.⁸¹ This effect is likely due to a function of mannitol as a free radical scavenger. Some commonly used antioxidants, such as thiosulfate and methionine, are effective in inhibiting antibody oxidation. The minimum effective levels (molar ratios of antibody to antioxidant) required to inhibit temperature-induced oxidation of rhuMAb HER2 were 1:5 and 1:25 for methionine and thiosulfate, respectively.⁸¹ However, use of thiosulfate has led to formation of a thiosulfate adduct of rhuMAb HER2.⁸¹ The safety of such a thio-containing adduct has not been reported.

One of the main excipients often used in antibody formulation is surfactants. They are usually

effective in reducing shaking/stirring-induced aggregation⁹¹ but may have negative effect during long-term storage.⁹² One obvious concern is that such compounds may contain a residual level of peroxides, which have been shown to cause protein oxidation.⁹³ Therefore, use of surfactants should be kept to a minimum in an antibody formulation if possible. For example, removing Tween 20 in a recombinant humanized monoclonal antibody HER2, rhuMAb HER2 solution reduced the oxidized antibody from 52% to <10% at 40°C.⁸¹

Effect of Shaking/Shearing

Both shaking and shearing can denature antibodies. It was found that shaking murine antibody-based products caused antibody precipitation and the shape of the precipitates are different depending on the fill volume.⁵³ In the evaluation of shear effect on the antigen-binding activity of a recombinant scFv antibody fragment in a buffer solution, Harrison et al.⁴⁵ found that the binding activity decayed at a mean rate constant of 0.83/h at a shear of approximately 20,000/s.

Effect of Preservatives

A limited number of studies have been conducted on the compatibility of preservatives with antibodies. Compatibility depends both on the antibody and the preservative. In the evaluation of the effect of several preservatives, including benzyl alcohol, chlorobutanol, methylparaben, propylparaben, phenol, and m-cresol, on the stability of a humanized monoclonal antibody, Gupta and Kaisheva⁹⁴ found that the antibody was most stable in the presence of methylparaben and propylparaben, compatible with benzyl alcohol and chlorobutanol at low concentrations, and not compatible with phenol and m-cresol, as measured by a variety of assays, including SEC-HPLC, DSC, light scattering, UV, and potency assay.

Effect of Processing Equipment

Another important issue in antibody formulation is the choice of proper processing equipment/containers. A few studies have shown that antibody stability can be significantly affected if an inappropriate choice is made. In the study of the stability of recombinant humanized monoclonal antibody HER2, rhuMAb HER2, in liquid formulations, Lam et al.⁸¹ found that replacing the stainless steel filler with a nonstainless steel filler

reduced the oxidized antibody (primarily Met-255) from 52% to 18% after storage for 2 weeks at 40°C. It was suggested that Fe ions, released from erosion of stainless steel by chloride ion at low pH, catalyzed the oxidation. In a similar case, Chen et al.²¹ demonstrated that a fully human anti-IL8 monoclonal antibody (ABX-IL8) in aqueous formulations containing 60 mM His had a higher level of aggregates after freeze-thaw in a stainless steel vessel and subsequent storage at 40°C, possibly due to the effect of Fe ions generated from a similar mechanism. In addition, proteins have been shown to facilitate metal corrosion.⁹⁵

Effect of Product Containers

The effect of product containers was clearly demonstrated in a recent study. McCormick et al.⁹⁶ reported that Tween 80, intended to replace human albumin in the original formulation, interacted with uncoated rubber stoppers in single-use Eprex syringes. The stoppers leached a small amount of plasticizers in the drug solution, which acted as an adjuvant, and caused a strong IgG response to the recombinant human erythropoietin. The immune response was significantly minimized later by switching to PTFE-coated rubber stoppers. In addition, headspace oxygen can accelerate oxidation of antibodies and replacement with an inert gas could minimize such a reaction.⁷³

Accelerated Stability Studies

To accelerate formulation development process, accelerated stability studies are usually conducted. However, estimation of room temperature or 5°C stability based on accelerated stability studies for antibodies, like other proteins, may or may not be possible or accurate. The unpredictability is due to the presence of complex and multiple degradation pathways, which may have different degree of temperature dependencies.¹⁰ Kroon et al.¹⁰ found that relative to other degradation pathways of a monoclonal antibody, OKT3 (IgG2a), Asn deamidation was preferentially accelerated with increasing temperature. Therefore, caution needs to be applied in interpreting such high-temperature-induced deamidation. On the other hand, Poborji et al.⁴¹ found that loss of monomeric chimeric antibody (L6) at pH 7.2 followed Arrhenius behavior in the temperature range of 30–50°C and extrapolation of the high temperature SEC data to 2–8°C at pH 7 and

5.5 resulted in comparable stability estimates with the available real-time data.

Lyophilized Formulation

Preparation of lyophilized protein formulations has been extensively reviewed.^{97–101} Like most proteins, some antibodies are not stable enough in a liquid form and lyophilized dosage forms will have to be considered. Lyophilization was suggested to be one of the two approaches in solving antibody aggregation.⁴⁷ This section will discuss some critical issues in formulating a lyophilized antibody product.

Amorphous Versus Crystalline State

It has been commonly believed that proteins are more stable in an amorphous state.¹⁰³ This is mainly because proteins need another excipient(s) to replace water molecules to form the required H-bonds as water molecules are removed during drying and a crystalline matrix does not provide intimate H-bonding between the excipient and the protein.^{104,105} It appears that if the protein itself can be crystallized during the lyophilization process (may be difficult practically), the protein could be more stable and might not need as much stabilizing agent as in the amorphous state. In a recent report, Shenoy et al.¹⁰⁶ compared the stability of two model proteins, glucose oxidase (GO) and lipase, and demonstrated that dry crystalline formulations are significantly more stable than their amorphous counterparts as monitored by size-exclusion chromatography. It remains to be seen whether this can be applicable to antibodies.

Effect of Formulation Excipients

To make a lyophilized antibody product, at least one formulation excipient, a bulking agent, is needed to confer an acceptable cake. If the antibody is not stable enough in the presence of a bulking agent during lyophilization or storage, a stabilizer(s) is included. The relative amount of formulation excipients (bulking and stabilizing agents) should be carefully chosen as these agents may affect each other's behavior, the tonicity, and stability of the lyophilized products.

Commonly used bulking agents include mannitol and glycine. Crystallization of these agents during lyophilization makes them wonderful bulking agents but poor stabilizing agents.⁵⁷ Although mannitol could stabilize an antibody as in the case

for a monoclonal antibody-vinca conjugate in a PBS solution at pH 7.4 upon lyophilization,⁶⁰ many studies showed that mannitol could not stabilize effectively or even destabilizes antibodies. Such examples include the aggregation of a lyophilized model recombinant humanized monoclonal antibody (rhuMAb HER2) in the presence of mannitol during storage.^{3,57} In the lyophilization of a human monoclonal antibody at 1 mg/mL, it was demonstrated that addition of 5% mannitol has no effect on the lyophilization-induced aggregation in PBS or physiological saline as measured by OD600 and addition of 10% mannitol actually accelerated aggregation during the lyophilization process.⁵⁸ On the other hand, when used in combination with sucrose or trehalose, similar degree of stabilization to that for sugar alone may be achieved such as the case for model recombinant humanized monoclonal antibody (rhuMAb HER2).⁵⁷ The disaccharide/mannitol formulations also inhibited deamidation of this antibody during storage to a greater extent than the lyoprotectant formulations alone.⁵⁷

Sugars are the most common stabilizing agents used in lyophilized formulations. Among these, two nonreducing sugars, sucrose and trehalose, are usually the first choice. Both sugars protected the stability of a few lyophilized antibodies equally well. These antibodies include lyophilized recombinant humanized monoclonal antibody, rhuMAb HER2,⁵⁷ IgG1 (containing 12 intra and 4 inter-chain disulfides),⁶² anti-IgG,¹⁰⁷ and chimeric monoclonal antibody.⁶⁴ However, sucrose seemed to be more effective in protecting a lyophilized IgG1 against aggregation during storage at 40°C at a sugar:protein weight ratio of 1:1 (Chang et al. 2005b).¹⁰² In another study, sucrose at 5% failed to offer any protection to a lyophilized mouse monoclonal antibody (MN12) (IgG2a (κ)) during storage at 56°C for 18 days.⁵⁹ Again, as mentioned in the liquid formulation section, even the most commonly used stabilizers may not stabilize all antibodies in the solid state and antibodies need to be treated as individually different molecules.

When sugars are used as stabilizing agents (lyoprotectants), a sufficient quantity needs to be used to achieve a significant effect depending on the protein concentration. It has been suggested that a molar lyoprotectant:protein ratio of 300:1 or greater should be used.⁴⁷ Indeed, the available literature data indicate a ratio higher than 300 is needed for better stabilization. It was shown that sugars protect the stability (aggregation and Asp isomerization) of a lyophilized, monoclonal

antibody (type not specified) to a significant level when the sugar to protein molar ratio was increased to 500:1, which happens to the theoretical number of water binding sites in the molecule.¹ Similarly, Andya et al.⁶² demonstrated that use of sucrose or trehalose inhibited the aggregation of a lyophilized antibody (IgG1—containing 12 intra and 4 interchain disulfides) during storage at 30°C to a maximum degree when the sucrose/trehalose:protein ratio was 500 or higher, which is roughly equivalent to the number of water-binding sites on the surface of the protein (550 estimated). Increasing the trehalose/anti-HER2 ratio from 60 mM (360 molar ratio) to 200 mM (1,200 molar ratio) significantly increased the stability (monomer by SEC-HPLC) of lyophilized formulation at 25 mg/mL at 40°C.¹⁰⁷ In a recent report, it was found that at least a weight ratio of 2:1 (molar ratio of about 800) was needed to achieve a maximum protection of a lyophilized sucrose:IgG1 formulation against both aggregation and chemical degradation during storage at 40°C (Chang et al. 2005a).¹⁰¹

Other formulation excipients were also used and some of these are effective in stabilizing certain antibodies. A recent study demonstrated that addition of sorbitol to a sucrose or trehalose formulation resulted in further enhancement of storage stability of a lyophilized IgG1 antibody (Chang et al. 2005b).¹⁰² Either dextran or HB- β -CD (better) protected the activity of a lyophilized mouse monoclonal antibody (MN12) (IgG2a (κ)) during storage.⁵⁹ Glucose was shown to inhibit gamma irradiation-induced fragmentation of humanized monoclonal antibodies (hr3).⁸⁵

Effect of Formulation “pH” and Buffering Agents

The pH of the liquid formulation can have a potential effect on the stability of the lyophilized formulation, even though the solid-state “pH” could not be well defined. In the evaluation of the stability of a lyophilized monoclonal antibody-vinca conjugate, aggregation seems to be lower at a neutral pH 7.1 than at either pH 8.5 or 6.1 when the lyophilized formulation was stored at 25°C.⁶⁰ In adjusting the formulation pH, use of a buffering agent may have effect on the antibody stability both during lyophilization and storage of the lyophilized products. For example, in the stability study of a fully human anti-IL8 monoclonal antibody (ABX-IL8; IgG2), Chen et al.²¹ demonstrated that addition of histidine inhibited the formation of HMW species upon lyophilization

and during storage at 37°C in a concentration-dependent manner. Among several excipients including His, Gly, mannitol, Glu, and polysorbate 20, His is the most critical in protecting solid-state stability of the antibody (minimizing aggregation). In a different study, the aggregation rate of a lyophilized anti-IgE at 5°C at 5 mg/mL in 10 mM buffer is affected both by pH and buffers in the following order: Na Phosphate, pH 7 > K Phosphate, pH 7 > Na Succinate, pH 6 or 5 > Histidine, pH 7.¹⁰⁷ It should be noted that some buffering agents may induce significant pH change due to selective crystallization during lyophilization, such as sodium phosphate. Such buffering agents should be avoided in preparing pH-sensitive antibody formulations.

Effect of Protein Concentration

In many cases, increasing the protein concentration increases the stability of the protein during lyophilization (see review).⁹⁸ However, antibodies do not seem to follow this trend and many antibodies have been shown to be less stable both during lyophilization and storage at high concentrations. For example, lyophilization of a human monoclonal antibody caused significant aggregation of MAb formulated in PBS or physiological saline as measured by OD600 and increasing the protein concentration from 1 to 2.5 or 5 mg/mL increased the OD600 from 0.194 to 0.311 or 0.427, respectively.⁵⁸ Similar trend was also observed during storage of lyophilized formulation. Increasing the concentration of a chimeric monoclonal antibody from 2.5 mg/mL to 25 mg/mL in a lyophilized formulation, containing 31 mg/mL sucrose, 15 mM NaCl, 0.02% Tween 80, 10 mM citrate, increased the aggregate level from 0.4% to 0.6% after 2 months at 5°C.⁶⁴ In the evaluation of the stability of a model recombinant humanized monoclonal antibody (rhuMAb HER2), Cleland et al.⁵⁷ demonstrated that increasing the protein concentration from 25 mg/mL to 50 mg/mL in a lyophilized formulation (containing 60 mM trehalose, 5 mM His at pH 6) increased the aggregate level from 8.5% to over 30% by SEC-after storage at 40°C for 44 months. Such behavior was also observed of anti-HER2 from 5 to 21 mg/mL containing 250 mannitol.¹⁰⁷

Effect of Moisture Content

The effect of moisture on the stability of lyophilized antibodies has not been consistent and seem

to depend on the antibody and the degradation pathways being monitored.⁵⁷ Generally, increasing moisture content of a lyophilized antibody will gradually increase the rate of degradation during storage. Such negative effect of moisture was clearly demonstrated in a variety of degradation pathways, including dimerization of T2G1s Fab' (IgG1 (κ)) in a moisture content range of 1.5–12.3%,⁶¹ aggregation of TNF-MAb between 0.68% and 8%,¹⁰⁸ formation of acidic/basic species of rhuMAb HER2 between 1% and 8.4%⁵⁷ and fragmentation of a mouse monoclonal antibody (MN12) with and without secondary drying.⁵⁹

In other cases, the effect of moisture is either complex or not significant. For example, Breen et al.¹ found that high-moisture formulations (8%) of a lyophilized monoclonal antibody (type not specified) showed a higher rate of aggregation, fragmentation, and Asp isomerization during storage than those containing 2% or 5% moisture but formulations containing intermediate moisture levels (2–3%) were less prone to aggregation than those containing a lower moisture levels (1%) as measured by SEC under accelerated storage conditions. Similarly, the aggregation of a lyophilized IgG1 was found to be minimal at an intermediate moisture level around 3% at different storage temperatures. (Chang et al. 2005b).¹⁰² In a different study, Cleland et al.⁵⁷ found that using a model recombinant humanized monoclonal antibody (rhuMAb HER2), a residual moisture between 1 and 8.4% had no impact on the rate of aggregation during storage at 2–8 or 40°C for 12 months.

Accelerated Stability Studies

Like antibodies in a liquid state, those in a solid state may or may not undergo degradation that is characteristic of Arrhenius behavior. It is generally believed that stability studies should be conducted at least below the glass transition temperature of the formulation. Duddu et al.⁶⁴ found that accelerated stability data generated in the glassy state (40°C) seems to be a better predictor of the relative stability of formulations than the data generated at a higher temperature (60°C). In the study of the stability of a high-concentration, lyophilized, monoclonal antibody (type not specified), Breen et al.¹ demonstrated that chemical and physical degradation pathways followed Arrhenius kinetics during storage in the glassy state. Only Asp isomerization followed the Arrhenius model above the T_g value.

Advanced Formulations

In addition to the liquid and lyophilized dosage forms on the market, other dosage forms have been tried and limited success has been reported.

Spray-Dried Formulations

Spray drying is an efficient way of preparing solid dosage forms because of the rapid removal of a solvent(s) from a drug solution. It is a very attractive alternative to lyophilization in preparing solid protein formulations. So far, a number of studies have been conducted for proteins and partly because of the high-temperature exposure in the process, albeit very short, limited success has been achieved. Protein aggregation during spray drying seems to be the major challenge.^{65,66,109,110}

Spray drying of antibodies has also been tried. As for other proteins, process-induced protein aggregation seems to be the major issue.^{71,110} Careful selection of proper excipients could minimize this problem. In the evaluation of a spray-dried formulation for a rhuMAbE25, it was demonstrated that trehalose or lactose minimized the aggregation during spray drying (aggregate dropped from 5–6% to ≤1%). For trehalose, the molar ratio for significant inhibition of aggregation is at or above 300:1 to 500:1 (excipient: protein).⁷¹ Such a ratio seems to be comparable with that used in the lyophilized formation. The addition of mannitol also reduced aggregation, but only up to a molar ratio of 200:1 and further increase in mannitol content resulted in crystallization, which had a detrimental effect on protein stability and aerosol performance.⁷¹ In a different study, either trehalose or sorbitol could inhibit IgG aggregation during spray drying.¹¹⁰

Stabilized Antibodies via Mutagenesis

Antibody fragments, such as scFv, are alternative antibody therapeutics. However, since their stability is not as good as full-length antibodies, mutagenesis, or chemical modifications have been tried to improve its stability. For example, R71A mutagenesis in the heavy chain of an unstable scFv dramatically increased its stability when incubated in human serum while having only a minor effect on the binding affinity of the molecule.¹¹¹ A more stable heavy chain, made through mutation, can increase the stability of

the light chain, and thereby confer more stability to the whole scFv.²⁴

Stabilized Antibodies via Chemical Modifications

The clinical performance of an antibody can be desirably changed by conjugation of the antibody to another entity. For example, McIntosh et al.¹¹² demonstrated that conjugation of carboxymethyl dextran to a tumor-antigen-specific monoclonal antibody (A5B7) increased the clearance of the antibody in mice but conjugation of cisplatin (*cis*-dichlorodiammine platinum II) with the antibody complex restricted its tissue distribution and reduced its systemic clearance.

PEGylated Antibodies

A common method of increasing plasma half-life of proteins is to increase the size of the protein by attaching a PEG moiety. Currently, there are at least four PEGylated commercial protein products on the market. However, the long plasma half-lives (as high as 7–23 days) of antibodies made much less appealing the development of such an antibody product. Since the long half-life was due to the binding of Fc to the Fc-receptor (neonatal Fc receptor, FcRn) in various tissues,^{33,35} antibody fragments, such as Fab' lacking the Fc portion have a much shorter half-life and could be good candidates for PEGylation. Such a modification was made on a humanized IgG Fab' fragment via site-specific attachment to an additionally engineered Cys residue, as modification via the lysine residues led to substantial losses in binding activity.²⁹

Controlled Release Systems

Controlled release systems have been extensively investigated for proteins in the past two decades.^{113,114} However, limited work has been conducted in this area for antibodies, partly due to their relatively long plasma half-lives compared with other proteins. To achieve long-term effect, a controlled released system consisting of biodegradable poly (lactic-glycolic) acid (PLGA) was prepared for an anti-cocaine catalytic monoclonal antibody and an *in vivo* release of the antibody for up to 10 days was demonstrated in mice following subcutaneous injection.¹¹⁵ It is anticipated that such systems could be useful if a minimum of 1-week duration of release is achieved.

SUMMARY

Antibodies have similar tertiary structures. The presence of a significant number of disulfide bonds and intimate domain–domain interactions in antibodies make them relatively stable and more resistant to moderate thermal stress compared to other proteins. Nevertheless, antibodies do experience a variety of instabilities similar to most proteins. These physical and chemical instabilities include denaturation, aggregation, surface adsorption, deamidation, oxidation, isomerization, fragmentation, etc. Due to the significant difference in the primary sequence among different antibodies, the relative severity of these degradation pathways can be significantly different. On the average, aggregation, deamidation, and isomerization seem to be more prevalent in antibodies.

Partly due to the stability difference, some antibody products are made into a liquid form while others are lyophilized (Tab. 1). The solution pH of these commercial products is either neutral or weakly acidic, suggesting that such a pH range is probably optimal for most antibodies. Surfactants have been used in most of these antibody products, presumably to inhibit antibody aggregation, and will likely be used in other antibody drug candidates. Two most commonly used formulation excipients in these antibody formulations are sucrose and NaCl. For liquid formulations, either one can be used if they offer the same level of stability protection. For lyophilized formulations, sucrose is preferable as NaCl does not form intimate H-bonds with the antibody and also reduce the glass transition temperature of formulation, making lyophilization less efficient. All the formulation excipients and buffering agents used in commercial antibody products or discussed in the article should be evaluated individually for each antibody drug candidate through stability studies before they are chosen as part of the product, as antibodies are structurally different.

The available stability data in the literature and the information on the commercial antibody products suggest that antibody formulation seems challenging but relatively manageable, compared to other protein drugs. Three major issues in antibody formulation are apparently challenging and need significant attention in the coming years: (1) development of stable high-concentration formulations, (2) management of the high-concentration-associated viscosity of these formulations,

and (3) minimization of antibody-formulation-induced immune response.

REFERENCES

- Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. *Pharm Res* 18:1345–1353.
- Roque ACA, Lowe CR, Taipa MA. 2004. Antibodies and genetically engineered related molecules: Production and purification. *Biotechnol Prog* 20: 639–654.
- Pavlou AK, Belsey MJ. 2005. The therapeutic antibodies market to 2008. *Eur J Pharm Biopharm* 59:389–396.
- Martsev SP, Tsybovsky YI, Stremovskiy OA, Odintsov SG, Balandin TG, Arosio P, Kravchuk ZI, Deyev SM. 2004. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. *Protein Eng Des Sel* 17:85–93.
- Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. *Drug Dev Res* 61:137–154.
- Janeway CA, Travers PA, Walport M, Shlomchik MJ. 2001. *Immunobiology*. New York: Garland Publishing.
- Zhang W, Czupryn MJ. 2002. Free sulfhydryl in recombinant monoclonal antibodies. *Biotechnol Prog* 18:509–513.
- Ruzheinikov SN, Muranova TA, Sedelnikova SE, Partridge LJ, Blackburn GM, Murray IA, Kakinuma H, Takahashi-Ando N, Shimazaki K, Sun J, Nishi Y, Rice DW. 2003. High-resolution crystal structure of the Fab-fragments of a family of mouse catalytic antibodies with esterase activity. *J Mol Biol* 332:423–435.
- Glockshuber R, Schmidt T, Pluckthun A. 1992. The disulfide bonds in antibody variable domains: Effects on stability, folding in vitro, and functional expression in *Escherichia coli*. *Biochemistry* 31: 1270–1279.
- Kroon DJ, Baldwin-Ferro A, Lalan P. 1992. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. *Pharm Res* 9:1386–1393.
- Wright A, Morrison SL. 1997. Effect of glycosylation on antibody function: Implications for genetic engineering. *Trends Biotechnol* 15:26–32.
- Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. *J Immunol* 143:2595–2601.
- Leibiger H, Wustner D, Stigler RD, Marx U. 1999. Variable domain-linked oligosaccharides of a human monoclonal IgG: Structure and influence on antigen binding. *Biochem J* 338:529–538.
- Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. *Pharm Res* 21: 897–903.
- Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* 278:3466–3473.
- Hunt G, Moorhouse KG, Chen AB. 1996. Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. *J Chromatogr A* 744:295–301.
- Jiskoot W, Beuvery EC, de Koning AAM, Herron JN, Crommelin DJA. 1990. Analytical approaches to the study of monoclonal antibody stability. *Pharm Res* 7:1234–1241.
- Wang L, Amphlett G, Lambert JM, Blattler W, Zhang W. 2005. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. *Pharm Res* 22: 1338–1349.
- Wan M, Shiao FY, Gordon W, Wang GY. 1999. Variant antibody identification by peptide mapping. *Biotechnol Bioeng* 62:485–488.
- Ramsland PA, Farrugia W. 2002. Crystal structures of human antibodies: A detailed and unfinished tapestry of immunoglobulin gene products. *J Mol Recognit* 15:248–259.
- Chen B, Bautista R, Yu K, Zapata GA, Chamow SM, et al. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. *Pharm Res* 20:1952–1960.
- Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, Woof JM, Perkins SJ. 2004. Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: A comparison with monomeric human IgA1. *J Mol Biol* 338:921–941.
- Bogard WC, Jr., Dean RT, Deo Y, Fuchs R, Mattis JA, McLean AA, Berger HJ. 1989. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. *Semin Nucl Med* 19:202–220.
- Worn A, Pluckthun A. 1998. Mutual stabilization of VL and VH in single-chain antibody fragments,

- investigated with mutants engineered for stability. *Biochemistry* 37:13120–13127.
25. Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. 1998. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. *Biochemistry* 37:9266–9273.
 26. Chan LA, Phillips ML, Wims LA, Trinh KR, Denham J, Morrison SL. 2004. Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions. *Mol Immunol* 41:527–538.
 27. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. 1997. Antibody structure, prediction and redesign. *Biophys Chem* 68:9–16.
 28. Oliva B, Bates PA, Querol E, Aviles FX, Sternberg MJE. 1998. Automated classification of antibody complementarity determining region 3 of the heavy chain (h3) loops into canonical forms and its application to protein structure prediction. *J Mol Biol* 279:1193–1210.
 29. Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. 2002. Formatting antibody fragments to mediate specific therapeutic functions. *Biochem Soc Trans* 30:512–516.
 30. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. 1993. Humanization of an antibody directed against IgE. *J Immunol* 151:2623–2632.
 31. Sheriff S, Chang CYY, Jeffrey PD, Bajorath J. 1996. X-ray structure of the uncomplexed anti-tumor antibody br96 and comparison with its antigen-bound form. *J Mol Biol* 259:938–946.
 32. Van Regenmortel MHV. 2002. Reductionism and the search for structure-function relationships in antibody molecules. *J Mol Recognit* 15:240–247.
 33. Lobo ED, Hansen RJ, Balthasar JP. 2004. Antibody pharmacokinetics and pharmacodynamics. *J Pharm Sci* 93:2645–2668.
 34. Coloma MJ, Trinh KR, Wims LA, Morrison SL. 1997. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. *J Immunol* 158:733–740.
 35. Stockwin LH, Holmes S. 2003. Antibodies as therapeutic agents: Vive la renaissance! *Expert Opin Biol Ther* 3:1133–1152.
 36. Cacia J, Keck R, Presta LG, Frenz J. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. *Biochemistry* 35:1897–1903.
 37. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. *J Chromatogr B Biomed Sci Appl* 752: 233–245.
 38. Dall'Acqua W, Carter P. 1998. Antibody engineering. *Curr Opin Struct Biol* 8:443–450.
 39. Le Gall F, Reusch U, Little M, Kipriyanov SM. 2004. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. *Protein Eng Des Sel* 17:85–93.
 40. Chu GC, Coulibaly SB, Raibekas A, Deechongkit S. 2005. Protein formulation of an IGG1 antibody with atypical glycosylation: A study on the stability of its glycoforms. *Abstr Pap Am Chem Soc* 229:U210–U211.
 41. Paborji M, Pochopin NL, Coppola WP, Bogardus JB. 1994. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. *Pharm Res* 11:764–771.
 42. Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H. 1999. Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. *Biochim Biophys Acta* 1431:120–131.
 43. Li SQ, Bomser JA, Zhang QH. 2005. Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G. *J Agric Food Chem* 53:663–670.
 44. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. *Int J Pharm* 185:129–188.
 45. Harrison JS, Gill A, Hoare M. 1998. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. *Biotechnol Bioeng* 59:517–519.
 46. Taschner N, Muller SA, Alumella VR, Goldie KN, Drake AF, Aebi U, Arvinte T. 2001. Modulation of antigenicity related to changes in antibody flexibility upon lyophilization. *J Mol Biol* 310:169–179.
 47. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. *J Pharm Sci* 93:1390–1402.
 48. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. *Pharm Res* 14:1472–1478.
 49. Demeule B, Gurny R, Arvinte T. 2005. Where disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates. *Eur J Pharm Biopharm*.
 50. Ryan ME, Webster ML, Statler JD. 1996. Adverse effects of intravenous immunoglobulin therapy. *Clin Pediatr* 35:23–31.
 51. Schreiber G. 2002. Kinetic studies of protein-protein interactions. *Curr Opin Struct Biol* 12: 41–47.
 52. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody

- at high concentrations and its relationship to noncovalent association. *Pharm Res* 21:1087–1093.
53. Levine HL, Ransohoff TC, Kawahata RT, McGregor WC. 1991. Use of surface tension measurements in the design of antibody-based product formulations. *J Parenter Sci Technol* 45:160–165.
 54. Ferri C, Zignego AL, Pileri SA. 2002. Cryoglobulins. *J Clin Pathol* 55:4–13.
 55. Lam XM, Oeswein JQ, Ongpipattanakul B, Shahrokh Z, Wang SX, Weissburg RP, Wong RL. 2000. Stabilized Antibody Formulation. Genentech, Inc., US Patent US 6991790 B1.
 56. Lee LS. 1997. Stabilized monomeric protein compositions. Enzon, Inc., US Patent US 5656730.
 57. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. *J Pharm Sci* 90:310–321.
 58. Hagiwara H, Yuasa H, Yamamoto Y. 2000. Stabilized human monoclonal antibody preparation, Yoshihide Hagiwara.
 59. Rensing ME, Jiskoot W, Talsma H, Van Ingen CW, Crommelin DJ, et al. 1992. Influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12). *Pharm Res* 9:266–270.
 60. Roy ML, Pikal MJ, Rickard EC, Maloney AM. 1992. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: A test of the WLF glass transition theory. *Dev Biol Stand* 74:323–339; discussion 340.
 61. Kamat MS, Tolman GL, Brown JM. 1996. Formulation development of an antifibrin monoclonal antibody radiopharmaceutical. *Pharm Biotechnol* 9:343–364.
 62. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. *AAPS PharmSci* 5:E10.
 63. Riggan A, Clodfelter D, Maloney A, Rickard E, Massey E. 1991. Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB. *Pharm Res* 8:1264–1269.
 64. Duddu SP, Dal Monte PR. 1997. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. *Pharm Res* 14:591–595.
 65. Maa YF, Nguyen PA, Andya JD, Dasovich N, Hsu CC, et al. 1998. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. *Pharm Res* 15:768–775.
 66. Maa YF, Nguyen PA, Hsu SW. 1998. Spray-drying of air-liquid interface sensitive recombinant human growth hormone. *J Pharm Sci* 87:152–159.
 67. Alexander AJ, Hughes DE. 1995. Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. *Anal Chem* 67:3626–3632.
 68. Hartmann WK, Saptharishi N, Yang XY, Mitra G, Soman G. 2004. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection. *Anal Biochem* 325:227–239.
 69. Doran PM. 2006. Loss of secreted antibody from transgenic plant tissue cultures due to surface adsorption. *J Biotechnol* 122:39–54.
 70. Morales AA, Nunez-Gandolfi G, Perez NP, Veliz BC, Caballero-Torres I, Duconge J, Fernandez E, Crespo FZ, Veloso A, Iznaga-Escobar N. 1999. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: Additives, biodistribution, and stability. *Nucl Med Biol* 26:717–723.
 71. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, Hsu CC, Shire SJ. 1999. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. *Pharm Res* 16:350–358.
 72. Usami A, Ohtsu A, Takahama S, Fujii T. 1996. Effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. *J Pharm Biomed Anal* 14:1133–1140.
 73. Rao PE, Kroon DJ. 1993. Orthoclone OKT3 chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody. In: Pearlman R, Wan YJ, editors. *Stability and characterization of protein and peptide drugs case histories*. New York: Plenum Press. p. 135–158.
 74. Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J, Strouse R, McGeehan P, Casas-Finet J, Schenerman MA. 2005. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. *Anal Chem* 77:2675–2682.
 75. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. *Crit Rev Ther Drug Carrier Syst* 10:307–377.
 76. Xie M, Schowen RL. 1999. Secondary structure and protein deamidation. *J Pharm Sci* 88:8–13.
 77. Kwong MY, Harris RJ. 1994. Identification of succinimide sites in proteins by N-terminal sequence analysis after alkaline hydroxylamine cleavage. *Protein Sci* 3:147–149.
 78. Zheng JY, Janis LJ. 2005. Influence of pH, buffer species, and storage temperature on physicochem-

- ical stability of a humanized monoclonal antibody LA298. *Int J Pharm* 308:46–51.
79. Tyler-Cross R, Schirch V. 1991. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. *J Biol Chem* 266: 22549–22556.
 80. Johnson RE, Qi H, Borgmeyer JR, Kessler RK, Zeng DL. 2004. Stable pH optimized formulation of a modified antibody. Pharmacia Corporation. International patent Wo2004/019861 A2.
 81. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. *J Pharm Sci* 86:1250–1255.
 82. Harris RJ. 1995. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. *J Chromatogr A* 705:129–134.
 83. Powell MF. 1996. A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: Reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. In: Pearlman R, Wang YJ, editors. *Formulation, characterization, and stability of protein drugs*. New York: Plenum Press. p. 1–140.
 84. Sarno MEC, Vasquez RA, Yung S-G, Graf CR. 1999. Stable intravenously-administrable immune globulin preparation. Baxter International Inc., US patent US5945098.
 85. Caballero I, Altanes S, Castillo A, Deridder V, Gomez T, Miralles Y, Naydenov V, Prieto E, Tilquin B. 2004. Radiosensitivity study of freeze-dried antibodies to Gamma irradiation. *Ame Pharm Rev* 7:40–46, 81.
 86. Kennedy DM, Skillen AW, Self CH. 1994. Glycation of monoclonal antibodies impairs their ability to bind antigen. *Clin Exp Immunol* 98:245–251.
 87. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. *Dev Biol (Basel)* 112:81–97.
 88. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. *J Pharm Sci* 94:1928–1940.
 89. Golovanov AP, Hautbergue GM, Wilson SA, Lian LY. 2004. A simple method for improving protein solubility and long-term stability. *J Am Chem Soc* 126:8933–8939.
 90. Kueltzo LA. 2004. Aggregation of monoclonal antibodies in aqueous solution with and without agitation. *Formulation Strategies for Protein Therapeutics*. Boston, MA: IBC Life Sciences.
 91. Mahler HC, Muller R, Friebeta W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. *Eur J Pharm Biopharm* 59:407–417.
 92. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. *Pharm Res* 19:511–516.
 93. Ha E, Wang W, Wang YJ. 2002. Peroxide formation in polysorbate 80 and protein stability. *J Pharm Sci* 91:2252–2264.
 94. Gupta S, Kaisheva E. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. *AAPS PharmSci* 5:E8.
 95. Kocijan A, Milosev I, Pihlar B. 2003. The influence of complexing agent and proteins on the corrosion of stainless steels and their metal components. *J Mater Sci Mater Med* 14:69–77.
 96. McCormick D. 2004. Small changes, big effects in biological manufacturing. *Pharm Technol* 28:16.
 97. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. *Pharm Res* 14:969–975.
 98. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. *Int J Pharm* 203: 1–60.
 99. Akers MJ, Vasudevan V, Stickelmeyer M. 2002. Formulation development of protein dosage forms. *Pharm Biotechnol* 14:47–127.
 100. Chang BS, Hershenson S. 2002. Practical approaches to protein formulation development. *Pharm Biotechnol* 13:1–25.
 101. Chang LL, Shepherd D, Sun J, Ouellette D, Grant KL, Tang XC, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix? *J Pharm Sci* 94:1427–1444.
 102. Chang LL, Shepherd D, Sun J, Tang XC, Pikal MJ. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. *J Pharm Sci* 94:1445–1455.
 103. Pikal MJ, Rigsbee DR. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. *Pharm Res* 14:1379–1387.
 104. Crowe JH, Crowe LM, Carpenter JF. 1993. Preserving dry biomaterials: The water replacement hypothesis, part 1. *Biopharm* 6:28–37.
 105. Crowe JH, Crowe LM, Carpenter JF. 1993. Preserving dry biomaterials: The water replacement hypothesis, part 2. *Biopharm* 6:40–43.
 106. Shenoy B, Wang Y, Shan W, Margolin AL. 2001. Stability of crystalline proteins. *Biotechnol Bioeng* 73:358–369.
 107. Andya J, Cleland JL, Hsu CC, Lam XM, Overcashier DE, Shire SJ, Yang JY-F, Wu SS-Y. 2004. Protein formulation. Genentech, Inc.
 108. Ma X, Wang DQ, Bouffard R, MacKenzie A. 2001. Characterization of murine monoclonal antibody

- to tumor necrosis factor (TNF-MAb) formulation for freeze drying cycle development. *Pharm Res* 18:196–202.
109. Maa YF, Costantino HR, Nguyen PA, Hsu CC. 1997. The effect of operating and formulation variables on the morphology of spray-dried protein particles. *Pharm Dev Technol* 2:213–223.
 110. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. 2005. Spray-drying of proteins: Effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. *Eur J Pharm Biopharm* 59:251–261.
 111. Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM. 2004. Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. *Br J Cancer* 90:1863–1870.
 112. McIntosh DP, Cooke RJ, McLachlan AJ, Daley-Yates PT, Rowland M. 1997. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. *J Pharm Sci* 86:1478–1483.
 113. Yewey GL, Duysen EG, Cox SM, Dunn RL. 1997. Delivery of proteins from a controlled release injectable implant. *Pharm Biotechnol* 10:93–117.
 114. Porjazoska A, Goracinova K, Mladenovska K, Glavas M, Simonovska M, Janjevic EI, Cvetkovska M. 2004. Poly(lactide-co-glycolide) microparticles as systems for controlled release of proteins—preparation and characterization. *Acta Pharm* 54:215–229.
 115. Homayoun P, Mandal T, Landry D, Komiskey H. 2003. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. *J Pharm Pharmacol* 55:933–938.